This is a promotional webinar, organised and funded by Gilead Sciences, Inc. for healthcare professionals practicing in the European Economic Area and Switzerland only. This material mentions Lyvdelzi▼ (seladelpar). EU Prescribing Information for seladelpar can be found here. EU SmPC can be found here. Prescribing information or conditions may vary from country to country, please refer to your relevant regulatory information. ▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Seladelpar was granted conditional approval by the European Commission (EC) for the treatment of PBC in combination with UDCA in adults who have inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA.
When was the last time you revisited how you manage primary biliary cholangitis (PBC)? Our understanding of PBC continues to evolve, from earlier diagnosis and risk stratification to treatment goals and emerging selective peroxisome proliferator-activated receptor (PPAR) delta second-line therapy. Watch our latest webinar, in which David Jones delivers an engaging and educational session highlighting seladelpar as a selective PPAR Delta agonist.
Topics covered:
- PBC treatment goals and second-line therapies
- Biochemical efficacy and liver stiffness measurement stabilisation
- Symptom response
- Safety and ease of use
Speaker:
David Jones
Professor of Liver Immunology, Newcastle University; Director, Newcastle University Centre for Research Excellence in Rare Disease, UK
